Acid-sensing ion channel 1a blockade reduces myocardial injury in rodent models of myocardial infarction

Written By CCRG

Redd MA, Yoshikawa Y, Khan N, Waqar M, Saez NJ, Outhwaite JE, Russell JS, Hanna AD, Chiu HS, Er SY, Butcher NJ, Mardon K, Fraser JF, Smythe ML, Rash LD, Thomas WG, King GF, Reichelt ME, Palpant NJ. Eur Heart J. DOI 10.1093/eurheartj/ehad793

Abstract: Myocardial infarction (MI) caused by ischemia-reperfusion injury (IRI) is the leading risk factor for heart failure. The sodium-hydrogen exchange (NHE) inhibitor, cariporide, is the only cardioprotective drug to reach Phase 3 clinical trials, but it caused cerebrovascular side effects. There remain no clinically approved drugs that block cardiomyocyte cell death during acute IRI.

CCRG
Previous

Hemorrhage and thrombosis in COVID‑19‑patients supported with extracorporeal membrane oxygenation
Next

Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study